Zydus Cadila Reels After Double FDA Warning
This article was originally published in PharmAsia News
Executive Summary
Shares of Cadila Healthcare were pounded on Indian bourses on New Year's Eve after the US FDA issued warning letters against two of the firm's Indian sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were already underway.
You may also be interested in...
Zydus Cadila Chief Passes On Baton To Scion
Cadila Healthcare’s scion Dr Sharvil Patel takes charge as managing director as the frontline Indian company transitions to its next phase of growth and aspires for a more innovation-driven avatar.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet